Pafuramidine

DB06532InvestigationalSmall molecule

Pafuramidine, a prodrug of furamidine, currently has orphan status for Pneumocystis jiroveci pneumonia.

Chemical structure of Pafuramidine
Primary indication
Investigated for use/treatment in pneumonia, trypanosomiasis, malaria, HIV infection, and infectious and parasitic disease (unspecified).Curator reviewed
Formula / weight
C20H20N4O3 · 364.405 g/mol (avg)

Resolves to

Compound
UNIIH1VG379J2XCAS186953-56-0ChEMBLCHEMBL319669
Clinical / RWD
RxNorm718967
Structure
InChIKeyUKOQVLAXCBRRGH-UHFFFAOYSA-NSMILESCONC(=N)C1=CC=C(C=C1)C1=CC=C(O1)C1=CC=C(C=C1)C(=N)NOC

What you can answer from here — as of September 13, 2026

4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which companies are running trials of Pafuramidine, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In